Condensed Statements of Cash Flows - USD ($)	6 Months Ended
	Dec. 31, 2025	Dec. 31, 2024
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (4,005,777)	$ (5,154,302)
Adjustments to reconcile net loss to net cash used in operating activities:
Preferred stock issued as compensation	23,216	28,413
Common stock issued as compensation and for services	223,350	84,000
Warrants granted to Scientific Advisory Board	258	383
Depreciation	261,768	387,362
Amortization	4,135	4,134
Changes in operating assets and liabilities:
Prepaid expenses	(33,839)	58,935
Other assets	713	8,817
Accounts payable	(240,781)	(124,413)
Accounts payable - related party	107,776	146,744
Accrued expenses	15,669	(225,881)
NET CASH USED IN OPERATING ACTIVITIES	(3,643,512)	(4,785,808)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(84,316)	(46,764)
NET CASH USED IN INVESTING ACTIVITIES	(84,316)	(46,764)
CASH FLOWS FROM FINANCING ACTIVITIES:
Net proceeds from sale of common stock, net of issuance costs	1,909,121	3,992,846
Net proceeds from sale of common stock and common stock warrants, net of issuance costs	5,410,723
NET CASH PROVIDED BY FINANCING ACTIVITIES	7,319,844	3,992,846
NET CHANGE IN CASH AND CASH EQUIVALENTS	3,592,016	(839,726)
Cash and cash equivalents at beginning of period	1,558,564	4,797,778
Cash and cash equivalents at end of period	5,150,580	3,958,052
NON-CASH INVESTING AND FINANCING ACTIVITIES
Cost related to sales of securities not paid	$ 6,742	$ 28,838